This Article Full Text (OnlineFirst PDF) All Versions of this Article: 1352458507082046v1 1352458507082046v2 14/2/183    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Villar, L. M. Articles by Álvarez-Cermeño, J.C. Search for Related Content PubMed PubMed Citation Articles by Villar, L. M. Articles by Álvarez-Cermeño, J.C. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Multiple Sclerosis Social Bookmarking                         What's this?

Influence of oligoclonal IgM specificity in multiple sclerosis disease course

Departments of Neurology and Immunology, Hospital Ramón y Cajal, Madrid, Spain

^* To whom correspondence should be addressed.

	Abstract

Oligoclonal IgM bands (OCMB) against myelin lipids predict an aggressive multiple sclerosis (MS) course. However, the clinical significance of OCMB without lipid specificity, present in other MS patients, remains unknown. We describe here a characterization of these antibodies and study their role in MS progression. Fifty-four MS patients showing CSF-restricted OCMB were included in this study at disease onset and followed-up during 61.1±2.7 months. The specificity of OCMB and the CSF B-cell profile were investigated. A second CSF IgM study was performed in a group of eight patients. Thirty-eight patients showed OCMB against myelin lipids (M+L+) and other sixteen had OCMB lacking this specificity (M+L-). The CD5+ B cell subpopulation, responsible for most persistent IgM responses, was considerably higher in M+L+ than in M+L- patients (3.3±0.6% versus 0.8±0.2, P=0.009). In addition, M+L+ bands persisted during disease course, while M+L- disappeared during follow-up. M+L+ patients suffered more relapses (4.2±0.6 versus 1.6±0.3, P=0.002) and reached higher disability (EDSS score of 2.2±0.2 versus 1.2±0.2, P=0.02) than M+L- group. These data corroborate that anti-lipid OCMB associate with an aggressive MS course and show that OCMB that do not recognize myelin lipids represent a transient immune response related to a more benign disease course. Multiple Sclerosis 2007; 00: 00–00. http://msj.sagepub.com

Key Words: antibodies; B lymphocytes; IgM; multiple sclerosis; oligoclonal bands; prognosis

First published on October 17, 2007, doi:10.1177/1352458507082046

Multiple Sclerosis 2008;14:183.

A more recent version of this article appeared on March 1, 2008
This version was published on January 31, 2008


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M Thangarajh, J Gomez-Rial, A. Hedstrom, J Hillert, J. Alvarez-Cermeno, T Masterman, and L. Villar Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis Multiple Sclerosis, November 1, 2008; 14(9): 1208 - 1213. [Abstract] [PDF]